Analysts Like Abbott’s Post-Health Reform Guidance

Abbott Laboratories’ first-quarter profit met Wall Street expectations on better-than-expected sales of its drug Humira, though the company lowered its profit outlook due to the impact of the health care overhaul.
Forbes